Biotin Status During Pregnancy

描述（由申请方提供）：尽管人们认识到生物素状态在人类妊娠期间（特别是在妊娠晚期）会受到损害，但尚未进行人类饮食研究来评估剂量-反应关系、母胎区室化或饮食生物素需求。因此，医学研究所的食品和营养委员会无法确定生物素的推荐膳食供给量（RDA）。相反，估计成人每天30 mcg生物素的充足摄入量（AI）水平，而未对孕妇进行向上调整。目标：本研究的目的是提供数据，为孕妇制定生物素RDA提供科学依据。具体目的：本提案的具体目的是：i）检验妊娠期间膳食生物素需求增加的假设; ii）检验母体和胎儿生物素状态生物标志物呈正相关的假设;和iii）研究膳食生物素摄入与生物素状态的经验证的生物标志物之间的剂量-反应关系。程序：为了实现这些目标，将延长在妊娠女性（n=10，21- 40岁，27周）和非妊娠对照女性（n=10，21-40岁）中进行的12周对照喂养研究，以评估这些女性中生物素的剂量反应。将沿着对饲料中生物素含量进行定量，同时测量母体/胎仔生物素状态的生物标志物，包括与生物素缺乏相关的生物标志物（即3-羟基异戊酸）和生物素催化剂（即双降生物素和生物素亚砜）。预期结果：本研究将能够描述人类母体和胎仔生物素状态之间的关系;深入了解可能导致妊娠期间观察到的次优生物素状态的因素;并有助于估计满足妊娠期间增加的需求所需的母体膳食生物素摄入水平，并确保发育中的胎儿获得充足的生物素供应。总的来说，这些数据有望为孕妇生物素RDA的开发提供科学信息，旨在改善孕产妇和胎儿健康。 公共卫生相关性：拟定的人体研究将检查生物素状态指标对已知膳食生物素摄入量的反应，评估母体和胎仔间生物素的分布，并研究母体和胎仔生物素状态指标之间的关系。预计本研究产生的数据将为制定孕妇生物素推荐膳食摄入量提供科学依据，并指导决定妊娠期间是否需要补充生物素。

DESCRIPTION (provided by applicant): Although it is recognized that biotin status is compromised during human pregnancy (particularly during the third trimester), no human dietary studies have been conducted to assess dose-response relationships, maternal-fetal compartmentation, or dietary biotin requirements. Consequently, the Food and Nutrition Board of the Institute of Medicine were not able to establish a recommended dietary allowance (RDA) for biotin. Instead an adequate intake (AI) level of 30 mcg biotin per day for adults was estimated without upward adjustments for pregnant women. Goal: The goal of this study is to provide data that will scientifically inform the development of a biotin RDA for pregnant women Specific Aims: The specific aims of this proposal are to: i) test the hypothesis that dietary biotin requirements are increased during pregnancy; ii) test the hypothesis that maternal and fetal biomarkers of biotin status are positively correlated; and iii) investigate the dose-response relationship between dietary biotin intake and validated biomarkers of biotin status. Procedure: To accomplish these aims, a 12-week controlled feeding study conducted in pregnant women (n=10, 21-40y, 27 wk) and nonpregnant control women (n=10, 21-40 y) will be extended to enable a dose response assessment of biotin in these women. Quantitation of the biotin content of the diet will be performed along with measurements of maternal/fetal biomarkers of biotin status including those linked to biotin deficiency (i.e. 3-hydroxyisovaleric acid) and biotin catabolism (i.e. bisnorbiotin and biotin sulfoxide). Expected Outcomes: This study will be able to delineate the relationship between maternal and fetal biotin status in humans; provide insight into the factors that may contribute to the suboptimal biotin status observed during pregnancy; and facilitate an estimation of the level of maternal dietary biotin intake required to meet the increased demands during pregnancy and ensure an adequate supply of biotin to the developing fetus. Collectively, these data are expected to scientifically inform the development of a biotin RDA for pregnant women that is designed to improve maternal and fetal health. PUBLIC HEALTH RELEVANCE: The proposed human study will examine the response of biotin status indicators to a known intake of dietary biotin, assess the distribution of biotin between maternal and fetal compartments, and investigate the relationship between maternal and fetal indicators of biotin status. The data generated from this study are expected to scientifically inform the development of a biotin recommended dietary allowance for pregnant women and guide decisions on the need for biotin supplementation during gestation.